Vosevi
Drug
Gilead Sciences Inc
Total Payments
$4.8M
Transactions
3,542
Doctors
331
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $6,478 | 3 | 0 |
| 2020 | $338,666 | 1 | 0 |
| 2019 | $354,852 | 23 | 0 |
| 2018 | $879,781 | 91 | 21 |
| 2017 | $3.2M | 3,424 | 328 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.2M | 640 | 67.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 661 | 22.4% |
| Travel and Lodging | $365,982 | 1,257 | 7.6% |
| Food and Beverage | $56,931 | 972 | 1.2% |
| Consulting Fee | $47,000 | 12 | 1.0% |
Payments by Type
Research
$3.2M
640 transactions
General
$1.5M
2,902 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety, Tolerability and Efficacy of Sofosbuvir, GS-5816, and GS-9857 in Subjects with previous DAA experience | Gilead Sciences, Inc. | $1.3M | 0 |
| Safety, Tolerability and Efficacy of Sofosbuvir, GS-5816, and GS-9857 in Subjects with previous DAA experience | Gilead Sciences Inc | $465,688 | 0 |
| POLARIS-1 A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection | Gilead Sciences Inc | $392,255 | 0 |
| An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects who Participated in a Prior Gilead-Sponsored HCV Treatment Study | Gilead Sciences Inc | $357,660 | 0 |
| POLARIS-2 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naive Subjects with Chronic HCV Infection | Gilead Sciences Inc | $161,735 | 0 |
| POLARIS-4 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS 9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor | Gilead Sciences Inc | $143,938 | 0 |
| POLARIS-3 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis | Gilead Sciences Inc | $103,189 | 0 |
| An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects who Participated in a Prior Gilead-Sponsored HCV Treatment Study | Gilead Sciences, Inc. | $63,913 | 0 |
| POLARIS-2 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naive Subjects with Chronic HCV Infection | Gilead Sciences, Inc. | $55,787 | 0 |
| POLARIS-4 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS 9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor | Gilead Sciences, Inc. | $52,449 | 0 |
| POLARIS-1 A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection | Gilead Sciences, Inc. | $40,629 | 0 |
| A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection | Gilead Sciences Inc | $27,119 | 0 |
| POLARIS-3 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis | Gilead Sciences, Inc. | $25,113 | 0 |
| A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Genotype 1 HCV Infection | Gilead Sciences Inc | $19,315 | 0 |
| A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Genotype 1 HCV Infection | Gilead Sciences, Inc. | $5,918 | 0 |
| TRILOGY-3 A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS 5816/GS-9857 Fixed-Dose Combination with or without Ribavirin in Subjects with Chronic Genotype 1 HCV Infection Previously Treated with a Direct Acting Antiviral Regimen | Gilead Sciences Inc | $3,250 | 0 |
| A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection | Gilead Sciences, Inc. | $1,146 | 0 |
Top Doctors Receiving Payments for Vosevi — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Dallas, TX | $5,125 | 13 |
| , MD | Internal Medicine | Phoenix, AZ | $5,123 | 9 |
| , M.D | Gastroenterology | Homewood, IL | $5,109 | 6 |
| , M.D | Gastroenterology | La Jolla, CA | $5,095 | 10 |
| , MD PHD | Hepatology | New Orleans, LA | $5,094 | 7 |
| , M.D | Transplant Hepatology | Orlando, FL | $5,090 | 11 |
| , MD | Internal Medicine | Houston, TX | $5,068 | 15 |
| , M.D | Gastroenterology | Oregon, OH | $5,065 | 8 |
| , M.D | Hepatology | El Paso, TX | $5,056 | 5 |
| , MD | Gastroenterology | Bronx, NY | $5,053 | 13 |
| , M.D | Gastroenterology | Arlington Heights, IL | $5,052 | 11 |
| , MD | Internal Medicine | Fort Worth, TX | $5,022 | 10 |
| , M.D | Internal Medicine | Kansas City, KS | $5,009 | 9 |
| , D.O | Gastroenterology | Tulsa, OK | $5,009 | 7 |
| , M.D | Gastroenterology | Merrillville, IN | $4,997 | 9 |
| , DO | Gastroenterology | Allentown, PA | $4,993 | 11 |
| , M.D | Gastroenterology | Rochester, MN | $4,987 | 11 |
| , MD | Gastroenterology | Wynnewood, PA | $4,987 | 14 |
| , MD | Internal Medicine | San Antonio, TX | $4,983 | 7 |
| James Lewis | Gastroenterology | Washington, DC | $4,963 | 6 |
| , M.D | Internal Medicine | Sweetwater, TN | $4,960 | 11 |
| , MD | Transplant Hepatology | Valhalla, NY | $4,951 | 11 |
| , M.D | Gastroenterology | Loma Linda, CA | $4,950 | 11 |
| , M.D | Infectious Disease | Sacramento, CA | $4,940 | 8 |
| , M.D | Gastroenterology | Colorado Springs, CO | $4,927 | 11 |
Ad
Manufacturing Companies
- Gilead Sciences Inc $3.2M
- Gilead Sciences, Inc. $1.6M
Product Information
- Type Drug
- Total Payments $4.8M
- Total Doctors 331
- Transactions 3,542
About Vosevi
Vosevi is a drug associated with $4.8M in payments to 331 healthcare providers, recorded across 3,542 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2021. In 2021, $6,478 was paid across 3 transactions to 0 doctors.
The most common payment nature for Vosevi is "Unspecified" ($3.2M, 67.8% of total).
Vosevi is associated with 17 research studies, including "Safety, Tolerability and Efficacy of Sofosbuvir, GS-5816, and GS-9857 in Subjects with previous DAA experience" ($1.3M).